Video & Transcript Research : 'pharmaceutical'
Page 4 of 55
MN
Transcript Highlights:
- requires drug pharmaceutical requires drug pharmaceutical manufacturers<00:13:53.080>
to < - And yet today we have pharmaceutical And yet today we have pharmaceutical companies<01:15:04.640
- >
the <01:15:30.840>US US pharmaceutical profits in the US US pharmaceutical profits in - Thanks. or do we stand with the pharmaceutical or do we stand with the pharmaceutical companies<01:18
- pharmaceuticals pharmaceuticals uh<01:30:19.000>
and <01:30:19.200>all <01:30:19.320>
OK
Oklahoma 2026 Regular Session
Senate Legislative Session Mar 24th, 2026 at 01:30 pm
Oklahoma Senate Floor Meeting
Transcript Highlights:
- So, to be clear, we're going to be appropriating funds to partner with the private pharmaceutical company
- Because my reading of it looks like it is using appropriated funds to give to a pharmaceutical company
- intent for this to be a temporary intervention or a permanent component of the state's approach to pharmaceutical
- Again, this is not about pharmaceutical access; this is about one drug that over 800,000 Oklahomans need
- I think insulin is a pharmaceutical, and we're talking about pharmaceutical access.
Bills:
SJR47, SB1491, SB1579, SB1806, SB1552, SB483, SB63, SB137, SB346, SB514, SB1344, SB1360, SB1380, SB1437, SB1189, SB1217, SB1221, SB1262, SB1272, SB1325, SB1339, SB201
Keywords:
voter ID, elections, constitutional amendment, Oklahoma, proof of identity, presidential electors, vacancies, oath of office, political party, property tax, valuation increase, taxpayer rights, homestead, protest process, foster care, adoption assistance, transitioning youth, Department of Human Services, voluntary services, county home rule charter
OK
Oklahoma 2026 Regular Session
Senate Legislative Session Mar 24th, 2026 at 09:30 am
Oklahoma Senate Floor Meeting
Bills:
SJR47, SB1491, SB1579, SB1806, SB1552, SB483, SB63, SB137, SB346, SB514, SB1344, SB1360, SB1380, SB1437, SB1189, SB1217, SB1221, SB1262, SB1272, SB1325, SB1339, SB201
Keywords:
voter ID, elections, constitutional amendment, Oklahoma, proof of identity, presidential electors, vacancies, oath of office, political party, property tax, valuation increase, taxpayer rights, homestead, protest process, foster care, adoption assistance, transitioning youth, Department of Human Services, voluntary services, county home rule charter
TX
Texas 89th Regular
Senate Committee on Health and Human Services (Part I) Apr 23rd, 2025
Health & Human Services
Transcript Highlights:
- So, I would agree that there are some situations regarding pharmaceuticals.
Bills:
SB128, SB640, SB672, SB904, SB1141, SB1263, SB1525, SB1528, SB2041, SB2306, SB2308, SB2357, SB2446, SB2695, SB2857, SB2891, SB2583
Keywords:
hospital reporting, child abuse, neglect, administrative penalty, medical ethics, child protection, SB 640, Texas Family Code, Department of Family and Protective Services, DFPS, child welfare, foster care, managing conservatorship, suicide attempt, youth suicide, mental health, child protective services, state custody, annual report, reporting requirements
TX
Texas 89th Regular
Senate Committee on Health and Human Services (Part II) Apr 23rd, 2025
Health & Human Services
Transcript Highlights:
- On December 14, 1995, the FDA approved Purdue Pharmaceuticals OxyContin for, quote, the management of
- So how do we guarantee through the FDA approval process and the pharmaceutical, would it be a. pharmaceutical
- So you can think from a pharmaceutical.
Bills:
SB128, SB640, SB672, SB904, SB1141, SB1263, SB1525, SB1528, SB2041, SB2306, SB2308, SB2357, SB2446, SB2695, SB2857, SB2891, SB2583
Keywords:
hospital reporting, child abuse, neglect, administrative penalty, medical ethics, child protection, SB 640, Texas Family Code, Department of Family and Protective Services, DFPS, child welfare, foster care, managing conservatorship, suicide attempt, youth suicide, mental health, child protective services, state custody, annual report, reporting requirements
CA
California 2025-2026 Regular Session
Assembly Budget Subcommittee No. 1 on Health Mar 3rd, 2025
Transcript Highlights:
- Supply costs have increased on average by 5% since COVID-19 officially ended, and pharmaceutical costs
- We partnered with Amnial Pharmaceuticals through an open request for information process.
- The pharmaceutical sector, as you know, is well known for being secretive and litigious.
- You mentioned the company was Amnial Pharmaceutical. How exactly were they chosen?
- Most pharmaceutical companies have lawsuits against them. That's probably true.
LA
Transcript Highlights:
- I will say Texas has had mandatory pharmaceutical price reporting since 2019.
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- Thank you, Chairman, Phil Christopher Nellie here with the Pharmaceutical Care Management Association
- This is an idea that came from the pharmaceutical manufacturers.
Summary:
The House Insurance Committee met on April 29 with a quorum present and took up several insurance and health care-related bills. SB 192, a dental reimbursement bill, was amended to allow dentists to opt in electronically to credit-card payment methods and to clarify applicability and effective date; it was reported as amended. SB 84 would require prostate cancer screening coverage for men over 40 under current clinical guidelines and prohibit cost-sharing; supporters from the American Cancer Society said Louisiana has a high incidence of prostate cancer and that out-of-pocket costs deter early screening. The committee adopted amendments and reported the bill as amended. SB 275, dealing with reimbursement and network participation for certified registered nurse anesthetists, drew support from nursing and hospital groups and was reported favorably. SB 169, a cleanup bill on biomarker testing, was also amended and reported.
The committee spent substantial time on SB 401, which creates a temporary prescription drug affordability board to review pricing data on selected drugs and report findings to the legislature. Supporters said the board would improve transparency and help lawmakers understand drug pricing trends; opponents raised concerns about confidentiality, market effects, and the lack of a defined policy outcome beyond reporting. Amendments narrowed the scope, added confidentiality protections, and removed opposition cards, and the bill was reported as amended. SB 387, a major PBM reform bill tied to SB 401, would change PBM compensation, rebate handling, formulary practices, audits, and appeals, while excluding ERISA plans after discussion and amendment. Supporters argued it would curb spread pricing and other practices that raise costs, while opponents from the Pelican Institute and PCMA warned it would interfere with private contracts, reduce flexibility, and could raise premiums or disrupt city, school board, and small-group plans. After extensive debate and a roll call, SB 387 was reported with amendments by a 10-4 vote.
The committee also considered SB 241, which requires certain insurance adjusters and public adjusters to include license numbers in written communications. After amendments limiting the requirement to individual licenses and removing one statutory reference, the bill was reported as amended. Throughout the meeting, members and witnesses repeatedly discussed the need for transparency in drug pricing and PBM practices, the role of ERISA and non-ERISA plans, and potential impacts on public employers and consumers.
LA
Transcript Highlights:
- I will say Texas has had mandatory pharmaceutical price reporting since 2019.
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- What you're going to hear from the PBMs is they're the only ones that are there keeping pharmaceutical
- This is an idea that came from the pharmaceutical manufacturers.
Summary:
The House Insurance Committee met on April 29 with a quorum present and considered several insurance- and health care-related bills. SB 192, concerning dental reimbursement and payment methods, was amended to clarify opt-in for electronic acceptance and then reported as amended. SB 84, which expands prostate cancer screening coverage for men over 40 and bars cost-sharing, was also amended and reported as amended after testimony from the American Cancer Society supporting earlier detection and reduced out-of-pocket barriers. SB 275, dealing with reimbursement and network access for certified registered nurse anesthetists, was reported favorably with broad support from nurse anesthetists, hospitals, and related groups. SB 169, a biomarker testing cleanup bill, was amended to clarify legislative intent and reported as amended.
The committee spent substantial time on two major drug-pricing bills. SB 401 would create a Prescription Drug Affordability Board to study selected prescription drug prices, collect manufacturer and related pricing data, and report findings to the legislature; amendments narrowed the scope, addressed confidentiality, and delayed implementation. Supporters said it would provide transparency similar to Texas and help lawmakers understand drug pricing, while opponents warned about government overreach and confidentiality concerns. SB 387, the companion PBM reform bill, would restrict PBM compensation to flat fees and performance bonuses, require rebate pass-throughs, limit formulary practices, expand audit and reporting requirements, and create enforcement mechanisms; it was amended to delay implementation, refine definitions, and address ERISA-related concerns. Supporters argued it would curb PBM abuses and lower drug costs, while opponents from the Pelican Institute and PCMA said it would interfere with private contracts, reduce flexibility, and could raise premiums. After a roll call vote, SB 387 was reported with amendments.
The committee also took up SB 241, which requires certain insurance adjusters and appraisers to include license numbers in written communications. After amendments narrowing the requirement to individual claims and public adjusters, the bill was reported as amended. Throughout the meeting, members repeatedly raised concerns about unintended consequences, especially for cities, school boards, and other non-ERISA plans, and sponsors said they would continue working on the drug-pricing bills before floor consideration.
MN
Minnesota 2025-2026 Regular Session
Facing Minnesota's Affordability Crisis by Addressing Healthcare Costs and Home Construction Hurdles May 1st, 2026
Minnesota Senate Floor Meeting
Transcript Highlights:
- How senators are stepping up enforcement efforts in the pharmaceutical industry to lower healthcare costs
- It's a federal program, and it's a good one that said pharmaceutical companies need to provide our safety
- It is raising costs of pharmaceuticals, and it's not helping patients.
- <00:11:46.640>
and raising costs of pharmaceuticals and raising costs of pharmaceuticals and it's - medical companies pharmaceutical medical companies pharmaceutical companies<00:12:09.520>
are
NY
Transcript Highlights:
- requiring prescription drug manufacturers to notify the Attorney General of arrangements between pharmaceutical
- By no means a patent attorney, particularly in the field of pharmaceuticals, but my understanding from
- duplicate process that the state is already governed by the federal government and we're dealing with pharmaceutical
- It's been raised by the pharmaceutical industry that this may actually...
- It's been raised by the pharmaceutical industry that this may actually... Thank you.
Summary:
The Senate Finance Committee, chaired for the day by Senator John Liu, took up a long agenda of bills covering labor and benefits, corrections, health, taxation, government transparency, and public services. Early measures included increasing short-term disability benefits, adjusting a poverty-level-related earned income disregard, expanding correctional health staffing review, and authorizing the Inspector General to investigate sexual assault complaints in correctional facilities; each of these advanced to the floor. The committee also advanced bills on ovarian cancer screening access, retirement system membership changes, a trail stewardship program, live agency representative access, FOIL/open meetings fee awards, a Harriman campus development plan, court data reporting, educator conventions, park water testing, an energy storage tax abatement, a Native American Affairs office, adult changing tables in public facilities, Medicaid Inspector General audit standards, remote training certification for agency personnel, newborn Gaucher disease testing, electronic self-exclusion requests for gambling, and child daycare inspections and opioid antagonist requirements.
Several bills drew discussion. The prescription drug transparency bill (Print 488A) prompted questions about possible overlap with federal Hatch-Waxman/FTC oversight and whether a New York notice requirement could slow generic-drug settlements; sponsors and staff said it was intended as a supplemental transparency measure for consumers. The court reporting bill (Print 1849A) raised concerns about mandates on local governments, but supporters said it mainly required OCA to compile data in one format. The Medicaid local-share phaseout bill (Print 5519) generated the most debate, with supporters arguing it would provide major property tax relief and should be addressed in the budget, while opponents emphasized the need to curb Medicaid fraud, waste, and abuse first.
Two major fiscal oversight proposals were defeated. Print 8661, which would have required the Comptroller to hire an independent private auditing firm to review state-funded programs for fraud and abuse, was opposed despite support from some members who argued outside auditing was overdue; it failed by one vote. Print 5519 was also ultimately defeated after a recount confirmed it lacked the required majority of the full 22-member committee. Most other bills were approved and sent either to the floor or, in the case of the drug transparency bill, to the Rules Committee.
CO
Colorado 2026 Regular Session
Colorado Senate 2026 Legislative Day 086 Apr 10th, 2026
Colorado Senate Floor Meeting
Transcript Highlights:
- It didn't come from pharmaceutical companies. They are not involved with this.
- It didn't come from pharmaceutical It didn't come from pharmaceutical companies.<00:35:44.040>
- , in licensing and sale of pharmaceuticals.
- , in the development of pharmaceuticals, in the development of pharmaceuticals, in<00:45:21.000><
- And we also have these pharmaceuticals.
Summary:
The Senate met with a quorum, approved the journal, and then proceeded out of order to consider Senate Joint Resolution 20, recognizing April 9, 2026, as Home Education Day in Colorado. Senator Pelton spoke in strong support of home education, describing it as a parent-led choice that benefits students and families. The resolution was adopted on a 30-0 vote, and the current roll was added as co-sponsors.
The chamber then took up the consent calendar and passed House Bill 1229, House Bill 1244, and Senate Bill 153. HB 1229, which concerns the human-animal bond as a social determinant of health, drew three no votes from Senators Pelton, Zamora Wilson, and Baeza; the other two measures passed unanimously. The Senate also laid over third reading of bills until Friday, April 10.
In Committee of the Whole, senators considered Senate Bill 72, which increases criminal penalties for assaultive conduct involving a motor vehicle and adds causing death with a motor vehicle to criminally negligent homicide. The committee adopted the report and advanced the bill on second reading. Later, the chamber laid over Senate Bill 134 and House Bill 1084 until April 10, and then took up Senate Bill 140, which would exempt certain rare disease and plasma therapies from review by the Prescription Drug Affordability Review Board. Sponsors and supporters argued the bill protects access for patients with rare diseases and prevents harm to treatment development, while opponents said it would weaken the PDAB’s affordability work and was too broad. Senators Weisman and Gonzales spoke against the bill, with Weisman citing concerns about the federal definition used and Gonzales defending the PDAB’s role in lowering drug costs; the debate continued in the transcript without a final vote shown.
MN
Minnesota 2025-2026 Regular Session
Minnesota House passes bill to cut wait times for prescribed opioid addiction treatment drugs Apr 27th, 2026
Minnesota House Floor Meeting
Transcript Highlights:
- It's still important that it's there, but this setting it up with our pharmaceuticals, our pharmacies
- It's still important that it's there, but this setting it up with our pharmaceuticals, our pharmacies
- It's still important that it's there, but this setting it up with our pharmaceuticals, our pharmacies
- It's still important that it's there, but this setting it up with our pharmaceuticals, our pharmacies
- Thank you. pharmaceuticals, our pharmacies in our communities will be a huge step forward.
Summary:
House File 4493 would authorize pharmacists to initiate, prescribe, administer, and dispense certain drugs for opioid use disorder, especially buprenorphine/Suboxone. Representative Baker said the bill is intended to save lives by giving people immediate access to treatment at the moment they seek help, rather than making them wait for a doctor’s appointment or navigate more cumbersome methadone access. He emphasized that pharmacists are widely accessible, including in greater Minnesota, and that optional training would support safe prescribing.
Representative Bierman spoke in strong support, calling the measure a life-or-death step forward for people with substance use disorder and noting that many people do not receive treatment when they need it. He said he initially had concerns but Baker listened to his suggested changes and worked with him and bill drafters, which helped address those concerns. Bierman also referenced the ongoing fentanyl crisis and encouraged members to learn more from displays honoring overdose victims.
Baker closed by sharing personal remarks about losing his son to addiction and describing how limited treatment options were at that time. He said the new federal change allowing pharmacist training makes the bill timely and urged members to support it. After discussion, the House took a roll call vote and passed the bill 134-0, with the title agreed to.
MN
Minnesota 2025-2026 Regular Session
Representatives Zeleznikar, Baker and Bierman Press Conference 5/12/26
Transcript Highlights:
- I would challenge the pharmaceutical industry to find a single player that makes claims anything close
- You may hear a lot of rhetoric from the for-profit trillion-dollar pharmaceutical companies that are
- companies that are busy pharmaceutical companies that are busy spending<00:26:12.880>
millions - Pharmaceutical company that is out of state, counting up their dough, make up your mind for you.
- go up for patients pharmaceuticals go up for patients because<00:32:26.159>
the <00:32:26.399>
Summary:
House File 369 was the main topic, with House authors Rep. Natalie Zeleznikar, Rep. Robert Bierman, and Rep. Dave Baker arguing that the bill would give Minnesota’s 2024 340B law “teeth” by enforcing protections for nonprofit and rural hospitals’ access to the federal drug pricing program. They said the measure costs the state nothing, aligns with similar laws in more than 20 other states, and is needed before adjournment to help hospitals close funding gaps, support services like emergency care, obstetrics, behavioral health, and pharmacy access, and preserve care in remote communities. Several hospital leaders from across greater Minnesota testified that 340B revenue helps keep their facilities viable and that losing it would threaten services and, in some cases, hospital survival.
Witnesses described severe financial pressure on rural hospitals, including reimbursement cuts, workforce shortages, inflation, and rising drug costs. Leaders from United Hospital District in Blue Earth, Lakewood Health System in Staples, Ely-Bloomenson Community Hospital, Northshore Health in Grand Marais, Community Memorial Hospital in Cloquet, and Cuyuna Regional Medical Center in Crosby said their hospitals serve as safety-net providers and often operate with thin or negative margins. They emphasized long travel times to other hospitals, seasonal tourism pressures in some areas, and the importance of local emergency, ambulance, inpatient, and specialty services. The Minnesota Hospital Association president also criticized pharmaceutical company messaging and said nonprofit hospitals are working around the clock to maintain access.
In response to questions, Zeleznikar said she had considered other enforcement approaches but now supported using the original Senate-passed bill, citing concerns about fraud and the difficulty of alternative enforcement mechanisms. She and hospital leaders distinguished this bill from a separate hospital stabilization-grant proposal, saying both are needed but serve different purposes. No vote was taken at the meeting, and the speakers repeatedly urged House leadership to bring the bill to the floor before session ends.
MN
Minnesota 2025-2026 Regular Session
Lowering the High Cost of Healthcare | Senator Matt Klein May 1st, 2026
Minnesota Senate Floor Meeting
Transcript Highlights:
- It's a federal program and it's a good one that said pharmaceutical companies need to provide our safety
- 34.320>
said program and it's a good one that said program and it's a good one that said pharmaceutical - companies<00:01:36.000>
need <00:01:36.240>to <00:01:36.400>provide pharmaceutical - companies need to provide pharmaceutical companies need to provide our<00:01:36.880>
safety <00 - So medical companies, pharmaceutical companies, are supposed to be using their money on research and
Summary:
The discussion focused on healthcare affordability in Minnesota and several related bills the senator said he is advancing this session. He described rising costs for Medicare beneficiaries, individual market purchasers, and hospitals, warning that federal changes to premium tax credits and Medicaid funding would worsen access and financial strain across the state. He said his goal is a comprehensive response to protect access to care, especially for safety-net and rural providers.
A major topic was Senate File 3769 on the 340B drug pricing program. The senator said the bill would empower the attorney general to enforce federal 340B requirements after pharmaceutical companies allegedly failed to provide discounted drugs to safety-net hospitals such as Hennepin County Medical Center and North Memorial. He said the measure passed both chambers with bipartisan support, after a nearly two-hour floor debate and significant lobbying by drug კომპანიies, and argued it could have an immediate effect by restoring hospital revenue and lowering medication costs for patients. He also said 340B is part of a broader effort to stabilize HCMC and other struggling hospitals.
The senator also discussed Senate File 3859, which would create a Minnesota vaccine advisory council to provide science-based recommendations after he said the federal advisory process had been undermined. He emphasized that the proposal would not require vaccinations, but would help counter misinformation and require insurance coverage for recommended vaccines. In addition, he supported Senate File 3650, a bipartisan bill to ban direct-to-consumer prescription drug advertising, arguing that such ads raise costs and can steer patients away from appropriate medical advice. No additional votes or committee actions were taken in the interview itself beyond the senator’s description of the 340B bill’s passage.
TX
Texas 89th 2nd C.S.
Health Care Affordability, Select Apr 30th, 2026
Health Care Affordability, Select
Transcript Highlights:
- American-manufactured drugs from pharmaceutical manufacturers here in the U.S.
- Are they pharmaceutical, or are they insurance? Which one?
- Situation because are they pharmaceutical, or are they insurance? Which one? In the middle?
- So my question has to do with the advertisement of pharmaceuticals on TV.
- And so I feel like pharmaceutical commercials.
TX
Transcript Highlights:
- you know, COVID brought us into a new awareness of the risks and problems with blind trust in pharmaceutical
- manufacturer can be held responsible when their defective product causes harm. harm someone, why not the pharmaceutical
- but for far too many, that trust was betrayed, not by their neighbors or their doctors, but by pharmaceutical
- Why should pharmaceutical companies be any different?
- That's the—so the federal, the— The federal law that gave pharmaceuticals the no liability was not so
Keywords:
sexual assault, healthcare facilities, forensic examination, survivor support, emergency contraceptive, online impersonation, civil liability, social media, identity theft, defamation, counseling damages, injunctive relief, public health, safety regulations, community health, state standards, healthcare access, HB 3336, alcoholic beverage tax credit, spent grain
TX
Transcript Highlights:
- you know, COVID brought us into a new awareness of the risk and problems with blind trust in pharmaceutical
- manufacturer can be held responsible when their defective product harms someone, why not the pharmaceutical
- but for far too many that trust was betrayed, not by their neighbors or their doctors, but by pharmaceutical
- Why should pharmaceutical companies be any different?
- That's, that's the attempt anyway, that's so The federal law that Gave pharmaceuticals the the no liability
Keywords:
sexual assault, healthcare facilities, forensic examination, survivor support, emergency contraceptive, online impersonation, civil liability, social media, identity theft, defamation, counseling damages, injunctive relief, public health, safety regulations, community health, state standards, healthcare access, HB 3336, alcoholic beverage tax credit, spent grain
US
US Federal 2025-2026 Regular Session
US House Floor Proceedings (Monday, April 20, 2026)
US Federal House Floor Meeting
Transcript Highlights:
- and pharmaceutical ingredients on the national security of the United States.
- In Proclamation 11020 of April 2nd, 2026, adjusting imports of pharmaceuticals and pharmaceutical ingredients
- I concur with the Secretary's findings that pharmaceuticals and associated pharmaceutical ingredients
- and pharmaceutical ingredients.
- and pharmaceutical ingredients, and the actions taken in the proclamation to eliminate that threat.
TX
Texas 89th 2nd C.S.
Senate Committee on Health and Human Services May 27th, 2026
Health & Human Services
Transcript Highlights:
- I will tell you this administration has done significant work in the pharmaceutical arena.
- Number two: pharmaceuticals. Nearly 10% of hospital expenses are on pharmaceuticals.
- Number two: pharmaceuticals. Nearly 10% of hospital expenses are on pharmaceuticals.
- Members, this part of the panel is really focused on the pharmaceutical portion of costs.
- I'm with the Pharmaceutical Care Management Association.
MN
Transcript Highlights:
- These are the three agencies that control pharmaceutical waste in Minnesota, and there are no compliance
- Man, I just had a question on what's the volume of dollars of pharmaceuticals that you have sent out
- So, uh, and you mentioned at the start $16 million of potential pharmaceuticals that go into the waste
- of pharmaceuticals that you have<00:15:51.199>
sent <00:15:51.440>out <00:15:51.680> - that go into potential pharmaceuticals that go into waste<00:16:09.360>
stream.
Keywords:
agriculture, education, leadership council, compensation, research institute, dairy assistance, investment relief, agriculture support, food production, economic relief, investment, relief initiative, farm support, medication repository, drug donation, healthcare, Minnesota Statutes, pharmacy, public health, controlled substances